<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02608177</url>
  </required_header>
  <id_info>
    <org_study_id>50084</org_study_id>
    <nct_id>NCT02608177</nct_id>
  </id_info>
  <brief_title>Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management</brief_title>
  <acronym>CANDY-CANE</acronym>
  <official_title>Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Diabetes Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to test whether a dipeptidyl peptidase-4 inhibitor, compared with a
      sulfonylurea, improves time in normal blood glucose range and reduces blood glucose
      variability. Blood glucose is measured using a continuous glucose monitoring device.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a proof-of-concept clinical trial testing the effects of linagliptin versus glipizide
      on glucose variability among people with type 2 diabetes and stage 3-4 CKD. In a cross-over
      design, each enrolled participant will receive 28 days of each study medication. Study
      medications will be provided in a randomly assigned order without blinding. The primary study
      outcome is glucose time in range, measured by blinded continuous glucose monitoring for the
      last 6 days of each 28-day treatment period. Secondary outcomes include indices of glycemic
      variability, hypoglycemia, and biomarkers of systemic inflammation, oxidative stress, and
      albuminuria. The overall goal of this research is to identify safe and effective treatments
      to control glycemia among patients with diabetes and CKD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">August 2018</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose Time in Range</measure>
    <time_frame>last 6 days of each 28-day treatment period</time_frame>
    <description>Time with glucose 70-140 mg/dL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glycemic Variability</measure>
    <time_frame>last 6 days of each 28-day treatment period</time_frame>
    <description>SD of glucose readings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia</measure>
    <time_frame>last 6 days of each 28-day treatment period</time_frame>
    <description>Glucose &lt;70 mg/dL for at least 10 minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of Systemic Inflammation</measure>
    <time_frame>last 6 days of each 28-day treatment period</time_frame>
    <description>Measured by plasma C-reactive protein (CRP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of Systemic Inflammation</measure>
    <time_frame>last 6 days of each 28-day treatment period</time_frame>
    <description>Measured by plasma interleukin-6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of Oxidative Stress</measure>
    <time_frame>last 6 days of each 28-day treatment period</time_frame>
    <description>Measured by plasma F2-isoprostanes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of Oxidative Stress</measure>
    <time_frame>last 6 days of each 28-day treatment period</time_frame>
    <description>Measured by urine F2-isoprostanes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of Albuminuria</measure>
    <time_frame>last 6 days of each 28-day treatment period</time_frame>
    <description>Measured by albumin-creatinine ratio</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Chronic Kidney Diseases</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Linagliptin/Glipizide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm receives 4 weeks of study drug linagliptin followed by 4 weeks of glipizide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glipizide/Linagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm receives 4 weeks of study drug glipizide followed by 4 weeks linagliptin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin</intervention_name>
    <description>Receives 4 weeks of study drug linagliptin</description>
    <arm_group_label>Glipizide/Linagliptin</arm_group_label>
    <arm_group_label>Linagliptin/Glipizide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glipizide</intervention_name>
    <description>Receives 4 weeks of study drug glipizide</description>
    <arm_group_label>Glipizide/Linagliptin</arm_group_label>
    <arm_group_label>Linagliptin/Glipizide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes

          -  eGFR 15-59 mL/min/1.73 m2

          -  Hemoglobin A1c &lt; 8%

          -  Age â‰¥ 18 years

          -  Current use of sulfonylurea

        Exclusion Criteria:

          -  BMI &gt; 40 kg/m2

          -  Actively using CGM for clinical care

          -  End stage renal disease needing dialysis

          -  Kidney transplant

          -  Pregnant or nursing

          -  Unable to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ian de Boer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>November 16, 2015</study_first_submitted>
  <study_first_submitted_qc>November 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2015</study_first_posted>
  <results_first_submitted>August 9, 2018</results_first_submitted>
  <results_first_submitted_qc>September 11, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 13, 2018</results_first_posted>
  <last_update_submitted>September 12, 2018</last_update_submitted>
  <last_update_submitted_qc>September 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Ian deBoer</investigator_full_name>
    <investigator_title>Associate Professor, Medicine/Nephrology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linagliptin</mesh_term>
    <mesh_term>Glipizide</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 28, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT02608177/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Linagliptin/Glipizide</title>
          <description>Arm receives 4 weeks of study drug linagliptin followed by 4 weeks of glipizide
Linagliptin: Receives 4 weeks of study drug linagliptin
Glipizide: Receives 4 weeks of study drug glipizide</description>
        </group>
        <group group_id="P2">
          <title>Glipizide/Linagliptin</title>
          <description>Arm receives 4 weeks of study drug glipizide followed by 4 weeks linagliptin
Linagliptin: Receives 4 weeks of study drug linagliptin
Glipizide: Receives 4 weeks of study drug glipizide</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Linagliptin/Glipizide</title>
          <description>Arm receives 4 weeks of study drug linagliptin followed by 4 weeks of glipizide
Linagliptin: Receives 4 weeks of study drug linagliptin
Glipizide: Receives 4 weeks of study drug glipizide</description>
        </group>
        <group group_id="B2">
          <title>Glipizide/Linagliptin</title>
          <description>Arm receives 4 weeks of study drug glipizide followed by 4 weeks linagliptin
Linagliptin: Receives 4 weeks of study drug linagliptin
Glipizide: Receives 4 weeks of study drug glipizide</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.3" spread="9.9"/>
                    <measurement group_id="B2" value="70.4" spread="NA">no SD due to one participant enrolled</measurement>
                    <measurement group_id="B3" value="68.3" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Non-Hispanic white race/ethnicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Glucose Time in Range</title>
        <description>Time with glucose 70-140 mg/dL</description>
        <time_frame>last 6 days of each 28-day treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Glipizide</title>
            <description>Outcome assessed among all participants in both treatment groups at the end of treatment with Glipizide for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin</title>
            <description>Outcome assessed among all participants in both treatment groups at the end of treatment with Linagliptin for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose Time in Range</title>
          <description>Time with glucose 70-140 mg/dL</description>
          <units>minutes per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="495.2" spread="671.9"/>
                    <measurement group_id="O2" value="573.3" spread="669.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glycemic Variability</title>
        <description>SD of glucose readings</description>
        <time_frame>last 6 days of each 28-day treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Glipizide</title>
            <description>Outcome assessed among all participants in both treatment groups at the end of treatment with Glipizide for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin</title>
            <description>Outcome assessed among all participants in both treatment groups at the end of treatment with Linagliptin for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Glycemic Variability</title>
          <description>SD of glucose readings</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.9" spread="16.1"/>
                    <measurement group_id="O2" value="41.5" spread="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hypoglycemia</title>
        <description>Glucose &lt;70 mg/dL for at least 10 minutes</description>
        <time_frame>last 6 days of each 28-day treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Glipizide</title>
            <description>Outcome assessed among all participants in both treatment groups at the end of treatment with Glipizide for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin</title>
            <description>Outcome assessed among all participants in both treatment groups at the end of treatment with Linagliptin for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Hypoglycemia</title>
          <description>Glucose &lt;70 mg/dL for at least 10 minutes</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biomarkers of Systemic Inflammation</title>
        <description>Measured by plasma C-reactive protein (CRP)</description>
        <time_frame>last 6 days of each 28-day treatment period</time_frame>
        <population>Labs not run due to small sample size.</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin/Glipizide</title>
            <description>Arm receives 4 weeks of study drug linagliptin followed by 4 weeks of glipizide
Linagliptin: Receives 4 weeks of study drug linagliptin
Glipizide: Receives 4 weeks of study drug glipizide</description>
          </group>
          <group group_id="O2">
            <title>Glipizide/Linagliptin</title>
            <description>Arm receives 4 weeks of study drug glipizide followed by 4 weeks linagliptin
Linagliptin: Receives 4 weeks of study drug linagliptin
Glipizide: Receives 4 weeks of study drug glipizide</description>
          </group>
        </group_list>
        <measure>
          <title>Biomarkers of Systemic Inflammation</title>
          <description>Measured by plasma C-reactive protein (CRP)</description>
          <population>Labs not run due to small sample size.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biomarkers of Systemic Inflammation</title>
        <description>Measured by plasma interleukin-6</description>
        <time_frame>last 6 days of each 28-day treatment period</time_frame>
        <population>Labs not run due to small sample size.</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin/Glipizide</title>
            <description>Arm receives 4 weeks of study drug linagliptin followed by 4 weeks of glipizide
Linagliptin: Receives 4 weeks of study drug linagliptin
Glipizide: Receives 4 weeks of study drug glipizide</description>
          </group>
          <group group_id="O2">
            <title>Glipizide/Linagliptin</title>
            <description>Arm receives 4 weeks of study drug glipizide followed by 4 weeks linagliptin
Linagliptin: Receives 4 weeks of study drug linagliptin
Glipizide: Receives 4 weeks of study drug glipizide</description>
          </group>
        </group_list>
        <measure>
          <title>Biomarkers of Systemic Inflammation</title>
          <description>Measured by plasma interleukin-6</description>
          <population>Labs not run due to small sample size.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biomarkers of Oxidative Stress</title>
        <description>Measured by plasma F2-isoprostanes</description>
        <time_frame>last 6 days of each 28-day treatment period</time_frame>
        <population>Labs not run due to small sample size.</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin/Glipizide</title>
            <description>Arm receives 4 weeks of study drug linagliptin followed by 4 weeks of glipizide
Linagliptin: Receives 4 weeks of study drug linagliptin
Glipizide: Receives 4 weeks of study drug glipizide</description>
          </group>
          <group group_id="O2">
            <title>Glipizide/Linagliptin</title>
            <description>Arm receives 4 weeks of study drug glipizide followed by 4 weeks linagliptin
Linagliptin: Receives 4 weeks of study drug linagliptin
Glipizide: Receives 4 weeks of study drug glipizide</description>
          </group>
        </group_list>
        <measure>
          <title>Biomarkers of Oxidative Stress</title>
          <description>Measured by plasma F2-isoprostanes</description>
          <population>Labs not run due to small sample size.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biomarkers of Oxidative Stress</title>
        <description>Measured by urine F2-isoprostanes</description>
        <time_frame>last 6 days of each 28-day treatment period</time_frame>
        <population>Labs not run due to small sample size.</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin/Glipizide</title>
            <description>Arm receives 4 weeks of study drug linagliptin followed by 4 weeks of glipizide
Linagliptin: Receives 4 weeks of study drug linagliptin
Glipizide: Receives 4 weeks of study drug glipizide</description>
          </group>
          <group group_id="O2">
            <title>Glipizide/Linagliptin</title>
            <description>Arm receives 4 weeks of study drug glipizide followed by 4 weeks linagliptin
Linagliptin: Receives 4 weeks of study drug linagliptin
Glipizide: Receives 4 weeks of study drug glipizide</description>
          </group>
        </group_list>
        <measure>
          <title>Biomarkers of Oxidative Stress</title>
          <description>Measured by urine F2-isoprostanes</description>
          <population>Labs not run due to small sample size.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biomarkers of Albuminuria</title>
        <description>Measured by albumin-creatinine ratio</description>
        <time_frame>last 6 days of each 28-day treatment period</time_frame>
        <population>Labs not run due to small sample size.</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin/Glipizide</title>
            <description>Arm receives 4 weeks of study drug linagliptin followed by 4 weeks of glipizide
Linagliptin: Receives 4 weeks of study drug linagliptin
Glipizide: Receives 4 weeks of study drug glipizide</description>
          </group>
          <group group_id="O2">
            <title>Glipizide/Linagliptin</title>
            <description>Arm receives 4 weeks of study drug glipizide followed by 4 weeks linagliptin
Linagliptin: Receives 4 weeks of study drug linagliptin
Glipizide: Receives 4 weeks of study drug glipizide</description>
          </group>
        </group_list>
        <measure>
          <title>Biomarkers of Albuminuria</title>
          <description>Measured by albumin-creatinine ratio</description>
          <population>Labs not run due to small sample size.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AE information collected over 8 weeks of the study</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Linagliptin/Glipizide</title>
          <description>Arm receives 4 weeks of study drug linagliptin followed by 4 weeks of glipizide
Linagliptin: Receives 4 weeks of study drug linagliptin
Glipizide: Receives 4 weeks of study drug glipizide</description>
        </group>
        <group group_id="E2">
          <title>Glipizide/Linagliptin</title>
          <description>Arm receives 4 weeks of study drug glipizide followed by 4 weeks linagliptin
Linagliptin: Receives 4 weeks of study drug linagliptin
Glipizide: Receives 4 weeks of study drug glipizide</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ian de Boer, Associate Director</name_or_title>
      <organization>Kidney Research Institute, University of Washington</organization>
      <phone>2067444029</phone>
      <email>IDeBoer@Nephrology.washington.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

